drugset / Trial / NCT05840588

Effect of Bifidobacterium Breve PRL2020 (an Amoxicillin-clavulanate-resistant Strain) on Gastrointestinal Symptoms and Gut Microbiota Composition in Children Treated With Amoxicillin or Amoxicillin/Clavulanate

NCT05840588

RandomizedParallel-groupOpen-labelTreatment

Summary

Amoxicillin or Amoxicillin/Clavulanic acid antibiotic therapy has been shown to be associated with disrupting the microbiota population particularly Bifidobacterium, which may have further GI clinical implications. The present randomized clinical trial is aimed to assess if probiotic Bifidobacterium breve PRL2020 (Brevicillin®) can help modulate the Bifidobacterium population and its clinical implications after antibiotic Amoxicillin or Amoxicillin/Clavulanic acid antibiotic therapy.

Timeline

Start
2023-11-06
Primary completion
2025-03-31
Completion
2025-04-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bifidobacterium breve PRL2020 Other / unclassified 2e+10 unknown
Background Amoxicillin Other / unclassified
Background clavulanic acid Small molecule